Brian Strom, Professor at the University Of Pennsylvania School Of Medicine, has expressed his concern over the current system of drug safety in U.S. According to him, the public usually misinterprets the drug safety process. They always expect that a drug is safe at the time of marketing.
Mr. Strom advises an optional approach with three points to make some changes in the drug safety process in U.S. The first point, according to him, is a need of conditional approval plan of drugs in place of currently running the ‘delay drug approval plan’.
The second point is to give necessary powers to the US Food and Drug Administration (FDA). FDA needs a greater-than-before capability to control drugs after marketing.
He made the last point by proposing an autonomous, nongovernmental organization for completing the academic tasks. It is needed to carry out the projects that are not within the job of the FDA.
Read